0.8979USD-1.33%Mkt Cap: 142.85M USDP/E: —Last update: 2026-05-26
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to dura…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap142.85M USD
Enterprise Value143.61M USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-140.95M USD
Revenue/Share—
Last Price0.8979 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.69
PEG—
EV/EBITDA-1.56
EV/Revenue—
P/S—
P/B6.62
EPS (TTM)-1.31
EPS (Forward)-0.54
52W Range
0.377020% of range3.030
52W High3.030 USD
52W Low0.3770 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1490.32%
ROA-116.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-90.33M USD
CapEx (TTM)557.00K USD
FCF Margin—
FCF Yield-36.20%
Net Debt-2.35M USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity6.52
Current Ratio4.28
Quick Ratio4.10
Book Value/Sh0.1390 USD
Cash/Share0.3980 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)5.240 USD
Target Range2.000 USD – 8.000 USD
# Analysts5
Ownership
Shares Out.158.65M
Float136.13M
Insiders1.31%
Institutions52.47%
Short Interest
Short Ratio1.8d
Short % Float2.03%
Short % Out.1.89%
Shares Short3.01M
Short (prev mo.)5.96M
Technical
SMA 500.5957 (+50.7%)
SMA 2001.113 (-19.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.24M
Avg Vol (10d)3.08M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—